Kyowa Kirin taps development insider for CEO post
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has named a long-time employee with extensive senior management experience in the drug and antibody development field as its next chief executive officer, signalling a renewed commitment to biologics as it takes a number of such therapies forward through late development.